 |
|
|
| |
A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naļve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Eric Lawitz,1 Gary Matusow,2 Edwin DeJesus,3 Eric Yoshida,4 Franco Felizarta,5 Reem Ghalib,6 Eliot Godofsky,7 Robert Herring,8 Gary Poleynard,9 Aasim Sheikh,10 Hillel Tobias,11 Marcelo Kugelmas,12 Ronald Kalmeijer,13 Monika Peeters,14 Oliver Lenz,14 Bart Fevery,14 Guy De La Rosa,15 Jane Scott,16 Rekha Sinha,13 James Witek13
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2The Gastroenterology Group of South Jersey, Vineland, NJ, USA; 3Orlando Immunology Center, Orlando, FL, USA; 4University of British Columbia, Vancouver, Canada; 5Private practice, Bakersfi eld, CA, USA; 6Texas Clinical
Research Institute, Arlington, TX, USA; 7University Hepatitis Center at Pointe West Infectious Diseases, Bradenton, FL, USA; 8Quality Medical Research, Nashville, TN, USA; 9Digestive Health Specialists, Winston-Salem, NC, USA; 10Gastrointestinal Specialists of Georgia, Marietta, GA, USA; 11Concorde Medical Group, New York, NY, USA; 12South Denver Gastroenterology, P.C., Denver, CO, USA; 13Janssen Research and Development, LLC., Titusville, NJ, USA; 14Janssen Infectious Diseases BVBA, Beerse, Belgium; 15Janssen Global Services, LLC., Titusville, NJ, USA; 16Janssen Global Services, LLC., High Wycombe, UK
|
| |
|
|
|
|
|
